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Abstract 
Paediatric non-alcoholic disease (NAFLD) is the most common chronic liver disease in childhood and 
adolescence. Though the condition is similar in many ways to NAFLD in adults, there are important differences 
in predisposition, presentation, differential diagnosis and potentially also in optimal management. Antenatal and 
early childhood exposures and the particular vulnerabilities in a growing child to environmental influences present 
unique opportunities for intervention and modification of risk. The prevalence of significant fibrosis on biopsy in 
pre-adolescent children in the context of NAFLD should not be ignored but the relevance of this fibrosis to long 
term outcome is as yet unknown.  Approach to children and adolescents with suspected NAFLD needs to include 
an assessment of risk factors in addition to exclusion of alternative or co-existing liver diseases. Liver biopsy is 
indicated in younger children and in those without clear predisposing factors leading to metabolic syndrome, also 
in those in whom significant fibrosis is suspected. The histology in children and adolescents differs from adults 
in that type 2 NAFLD may be more prevalent, which is associated in turn with more significant fibrosis. 
Management in children and adolescents needs to focus on lifestyle intervention, which, when weight loss is 
achieved, demonstrates excellent results in terms of resolution of disease. Appropriate intervention in childhood 
and adolescence where may prove instrumental in avoiding the need for later transplantation while also decreasing 
all-cause mortality in these at-risk individuals.   
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Introduction  
 
NAFLD is rapidly becoming the most common indication for liver transplantation liver in the western world (1). 
Paediatric NAFLD is thought of as an early presentation of the adult condition and in general is thought not to 
frequently progress to decompensated end stage liver disease nor hepatocellular carcinoma in childhood. That 
said, paediatric NAFLD presents both challenges and opportunities in terms of both diagnosis and management. 
Several important distinctions exist between adult and paediatric disease which need to be understood before we 
can effectively approach management. It is not clear why some patients with NAFLD present during childhood 
with often significant fibrosis; it is possible that this is merely incidental and the course of disease is still over 40 
– 50 years prior to end stage. The alternatives, however, are that paediatric NAFLD is a distinct disease with 
different susceptibilities and pathophysiology than the adult disease or that presenting in early life forebodes more 
significant or severe disease (2). The question of the long-term outcome of those with paediatric-onset NAFLD is 
as yet unanswered.  
 
In the first instance, early life susceptibilities to the condition are most often identifiable in paediatric versus adult 
onset NAFLD. Preconception maternal obesity and gestational diabetes are recognised as important risk factors 
which need to be addressed at a societal and preventative level (3). Early feeding practices, weaning and the 
exposure of children to the dangers of the high sugar westernised diet particularly during a vulnerable stage of 
development are all relevant. The rapid physical and psychological changes that occur during adolescence where 
insulin resistance peaks and body mass is laid down are critical periods where metabolism is regulated and may 
also be important in establishing or avoiding liver damage.  
This review will approach paediatric NAFLD from the viewpoint of a comparison to adult disease and the different 
approach that may be taken in light of this distinction.  
 
 
 
 
 
Epidemiology 
 
NAFLD is thought to affect 10% of children under the age of 18 years as demonstrated by a post mortem study 
of livers of children and young people who suffered unnatural death. Steatosis was found in 9% of children with 
3% having evidence of liver inflammation / fibrosis (4). Epidemiological studies are less likely to use histological 
definitions of the disease and the prevalence varies accordingly. When ultrasound is used to assess steatosis, 
prevalence varies from 1.8% in a normal population of children and young people to 60% of children and young 
people undergoing bariatric surgery to 80% of those in an obesity clinic (5-7).  
These figures are not far from adult prevalence and are closely linked to the prevalence of obesity. Severity of 
disease in children does not necessarily associate directly with severity of obesity for example and possibly 
different prenatal and childhood exposures on a genetically susceptible individual may predispose to early onset 
of disease. The degree of obesity in an individual does not correlate to severity of liver disease in that 
individual(8). The concept that those with certain genetic susceptibilities should have a ‘normal’ BMI which may 
be less than the conventional ‘normal’ holds true for this condition.  
 
Susceptibility   
 
The effects of the intrauterine environment in terms of priming may be more relevant to paediatric patients in 
terms of developing NAFLD (9). Both small for gestational age and large for gestational age infants are 
overrepresented in those who develop NAFLD during childhood and adolescence(10). Intrahepatic lipid content 
investigated using MRI is higher in infants of mothers who were obese and those with type 2 diabetes than in 
those born to normal weight mothers (11, 12). Interestingly intrahepatic fat content was more closely related to 
maternal BMI than to birthweight (12). In a post mortem study of stillborn infants, those born to mothers with 
gestational debates had a prevalence of 78.8% steatosis versus those still born infants of mothers who were not 
diabetic (13). Deposition of subcutaneous fat does not occur until the third trimester this it is conceivable that 
there is hepatic storage of excess substrate in the fetal liver, in addition to in utero de novo lipogenesis in response 
to a high transplacental glucose supply (9). Insulin does not cross the placenta but it is thought to increase placental 
inflammation altering the transfer of nutrients to the fetus. In addition, increased fatty acids signal placental Toll 
like receptor 4 expression, again this proinflammatory response may increase fetal nutrient transport (14). 
Placental insufficiency has also been associated with a higher inflammatory milieu and increased metabolic risk 
(15). There is a clear relationship between maternal obesity and BMI in childhood (16, 17). It is thus likely that 
the consequent complications of obesity including NAFLD will follow this increased risk (18).  
The link between antenatal and early postnatal exposure and NAFLD is complex and multifactorial. In part the 
possibility that the microbiome may be involved in establishing susceptibility to poor metabolic health. Infants 
with decreased microbiome diversity at 6 months are greater risk obesity aged 7 years (19). It is known that 
immune tolerance is promoted by gut microbiota, this is also decreased in number in offspring of obese women . 
Breast feeding, which has shown to be protective against NAFLD in some studies (though the confounding 
principles of socioeconomic influences on this observation is difficult to unpick) may act in part at least via the 
microbiome, though the confounding issue of socioeconomic influence . Breast feeding promotes colonisation of 
the intestinal microbiome providing oligosaccharides as prebiotics(18).  
 
Animal studies can elucidate further the antenatal risk to the fetus and the compounding influence of early life 
exposure. In mice, a study reported the influence of high fat diet (HFD) in dams and in pups versus controls. HFD 
in dams led to fatty liver in offspring, this was seen to a greater extent when the pups were also fed HFD but also 
seen in normal fed chow fed pups. Both high fat diet pre and post pregnancy leads to a cumulative risk (20). Both 
DNA methylation alteration (21) and a decrease of diversity in the microbiome are both possible mediators of this 
effect. Another mouse model of maternal obesity demonstrated higher oxidative stress and impairment of innate 
immunity in pups following an in utero high fat diet. At 12 months the pups showed steatohepatitis and fibrosis 
with an increased number of inflammatory and fibrogenic mediators (22). 
 
A similar experiment in rats demonstrated a sex prediction in that male offspring of high fat dams demonstrated 
more injury than females;  possibly due to the different growth trajectory expected in male versus female pups 
(23).  
 
Non-human primates fed a high fat diet prior to breeding which was then normalised during pregnancy 
demonstrated that effects on offspring can be modified. An increased liver triglyceride content with increased 
expression lipogenic genes in liver tissue and increased activation of inflammatory gene expression was 
demonstrated in these animals (24).  
 
 
Genetics  
 
In terms of genetic susceptibility, findings in children largely mirror those in adults with the minor allele of 
PNPLA3 (rs738409) widely reported as a susceptibility factor (25, 26) and frequency varies according to ethnicity 
of the patients affected.  Other genetic variants such as TM6SF2 rs58542926 (27) (28) and GCKR (29) are 
implicated in susceptibility but there have been few widespread paediatric GWAS studies and only one in biopsy 
proven- NAFLD in children(30). In this study 234 Hispanic boys were investigated for genetic variations 
predisposing them to NAFLD. In addition to PNPA3 and TMSF6, the authors found that novel variants in 
Trafficking Protein Particle Complex 9 (TRAPPC9) were associated with the NAFLD activity score (NAS) and 
a single nucleotide polymorphism (SNP) in a region close to ARP5 – actin related protein 5 was associated with 
fibrosis.  
Clearly genetic variation plays some part but is not in itself sufficient to explain propensity to disease. Given that 
even within the obese population, genetic susceptibility only comprises part of the risk, much focus has been 
given to dietary components and whether specific diets convey risk.  
 
Dietary intake  
 
Many studies have drawn associations between the intake of fructose, saturated fat and decreased fibre intake, 
polyunsaturated fats and the development of NAFLD (31).  Children have a particularly high consumption of 
fructose containing sweetened beverages up to 300kcal / day (32). In addition children have the highest intake of 
ultra-processed food at 33% (32.1-35%) versus adults 29.6% (28.5 – 30.7%) (33). Both have been linked to poor 
metabolic health including NAFLD. Indeed, the consumption of a Western diet was strongly associated with 
NAFLD in both Australian (34) and Chinese adolescents (35). A review of children with biopsy proven NAFLD 
compared to obese controls in the UK did not reveal any major dietary differences between the two groups 
however the NAFLD group tended to be lighter and more active in general (36). It is difficult to conclude that 
inclusion or exclusion of one or more component of diet may make a difference to the development and 
progression of NAFLD in children.  
 
Diagnosis  
 
The diagnosis of NAFLD in children brings challenges. Though significant alcohol consumption particularly in 
children less than 14 years is unlikely to play a major contribution to liver injury many other liver diseases of 
childhood may present with steatosis with or without inflammation and fibrosis. Given that 30% of the paediatric 
population worldwide is overweight or obese (37), in those presenting with Wilson disease or other Hepatitis C 
the presence of overweight and obesity equates to the population norm. Thus, the presence of overweight or 
obesity does not mean that a child with steatosis does not have an alternative diagnosis to NAFLD! The work up 
for fatty liver, usually found incidentally when a child has blood tests for another reason and goes on to have an 
ultrasound scan due to abnormal LFTs, should be comprehensive (38). In addition to screening for associated 
features of the metabolic syndrome such as fasting lipid levels, hypertension, HbA1C, HOMA-IR and impaired 
glucose tolerance, children should undergo a work up for alternate liver conditions. This should include but is not 
limited to infectious hepatitis, Wilson disease, inborn errors of metabolism (fatty acid oxidation disorders, 
mitochondrial disease), coeliac disease, alpha 1 antitrypsin deficiency and abnormalities of lipid metabolism (for 
example; hypobetalipoproteinemia). There are several other conditions that may be investigated based on clinical 
suspicion and summarised in Table 1. In addition, a full family, feeding and medication history should be taken. 
Parenteral nutrition and medications such as steroids, antipsychotics and antidepressants may all predispose to 
weight gain and steatosis.  
 
Though the definition of NAFLD is a histological one, non-invasive methods to detect and stage the disease are 
now common in clinical practice (39). The most useful is ultrasound which can detect > 30% steatosis which is 
probably the level at which it is most clinically significant. ALT, AST and GGT levels may reveal liver 
inflammation at a point in time but will not reliably differentiate those with and without fibrotic disease which is 
the main determinant of outcome.   
Radiological techniques such as MRS and MRI proton dense fat fraction will differentiate different grades of 
intrahepatic lipid and MR elastography is a useful measure of liver stiffness – a proxy for fibrosis (40, 41). MRI 
is expensive and cumbersome however and not suited to day-to day clinical practice though can be a useful 
research tool.  
Transient elastography is well validated in paediatric as well as adult studies to detect fibrosis in NAFLD (41, 
42). The relatively new controlled attenuation parameter measurement may also prove useful in quantifying 
steatosis in a longitudinal manner but use in children has not been adequately validated as yet (43).    
Acoustic radiation force imaging and other types of shear wave elastography (aside from TE), are other emerging 
methods of detection and quantification of fibrosis (44). They have not yet been extensively validated in paediatric 
patients with NAFLD though encouraging reports are emerging (45).   
 Such is the enormity of the prevalence of NAFLD in the population, the question of who and when to refer to the 
paediatric hepatologist is a difficult one. In general, in those with a fatty liver on ultrasound, NAFLD is a diagnosis 
of exclusion. In the absence of the typical phenotype, other conditions must be suspected first. Even in those with 
other features of the metabolic syndrome and a relevant family history of NAFLD, other or co-existing disease 
should be suspected. Severity of disease is not easy to elucidate in primary care. Several algorithms have been 
developed in large adult cohorts to differentiate significantly fibrotic disease. Unfortunately, most are not 
applicable to children given that they include age, BMI (adult reference) or markers of collagen turn over. For 
example, it is well established that FIB4 is unreliable in those under the age of 35 years (46), the fatty liver index 
uses BMI, the absolute number of which is not applicable to children (rather need BMI z score or centile) (47). 
ELF score uses P3NP as a variable which is an age and sex dependent marker of collagen turn over.  
The Pediatric NAFLD score is the only paediatric-specific algorithm, but still has not been validated outside of a 
Caucasian Italian population (48).  
Thus, as per both ESPGHAN and NASPGHAN guidelines, we first need to cautious about making a positive 
diagnosis of NAFLD, considering relevant differential diagnosis (49, 50).  
Histological diagnosis is ideal though only rarely practical. Assessing severity of disease is focused on detection 
and staging of fibrosis. Until such time that appropriate serum biomarkers or algorithms are available and 
validated, the non-invasive determination of degree of fibrosis is still limited to larger centres which have transient 
elastography or other imaging techniques for fibrosis readily available.    
 
Histology 
 
Typical ‘paediatric’ NAFLD differs histologically from that in adults (51). This pattern, found predominantly in 
children and young people has been labelled ‘type 2 NAFLD’ and is periportal in distribution versus the largely 
pericentral disease in adults. In various series the prevalence of type 2 histology differs(51, 52). Often, children 
may have a mixed type 1 and type 2 pattern. In type 1 NAFLD, steatosis, inflammation and fibrosis are mainly 
lobular, surrounding the central vein. In type 2, steatosis, inflammation and fibrosis are preferentially periportal. 
Ballooning, one of the classical histological features of NAFLD, is less common in children with type 2 disease 
Table 3 – differences  
 
The NAFLD activity score (NAS) developed by a collaboration of pathologists using material from adults and 
children with NAFLD through the NASH clinical research network (53). It is the most commonly used scoring 
system in the literature and is based on a score of 0 – 3 for steatosis, 0 – 2 for ballooning and 0 – 3 for lobular 
inflammation. Fibrosis is scored separately from 0 to 4. The diagnosis of non-alcoholic steatohepatitis from a 
research perspective is based on a NAS score of 5 or more. A score of 2 or less is not NASH and 3 or 4 is 
borderline.  Children tend to score lower on the NAS due to less lobular inflammation and ballooning.   The 
presence of NASH was previously thought to be the most important prognostic factor in determining outcome in 
patients with NAFLD. It is now recognised however that the presence of fibrosis is a more reliable predictor of 
outcome, not least as the degree of inflammation in a biopsy may change over days to weeks (54).  
 
The presence of type 2 disease is associated with more advanced fibrosis and progressive disease (55). Steatosis 
may be macro or microvesicular or both. The presence of microvesicular steatosis should prompt the possibility 
of mitochondrial disorders or other inborn errors of metabolism, though the prevalence of microvascular steatosis 
in adult onset NAFLD is reported and associated with greater severity of disease.  
The reason that children demonstrate relatively greater prevalence of type 2 disease is not entirely clear. We 
speculate however that it may possibly be linked to the development of zonation in the liver lobule (56, 57). 
Enzymes involved in Kreb’s cycle for example found mostly in zone 1 in the periportal region. Hepatocytes 
responsible for detoxification and metabolism due to the p450 mechanism are preferentially located in zone 3 
(perivenular).  It is possible that the differential function along the lobule may predispose children to susceptibility 
to injury at different stages of development (56, 57).   
 
 
Natural history and treatment  
 
A handful of case series have reported on the long-term follow up of children with NAFLD including the need 
for liver transplantation at an early age, though be it rare (58-60). The difficulty with assessment of severe 
paediatric fatty liver disease is the concern that an alternative undiagnosed metabolic disease may be present, 
particularly in the case of ‘lean NAFLD (38). In adults it is thought to take approximately 7 years to progress one 
fibrosis stage (60). A study analysed paired liver biopsies from 122 children who were in the placebo group in 
two randomised clinical trials for NAFLD (lifestyle advice only for either 52 or 96 weeks). During the trial period, 
the fibrosis stage progressed in 23%, and improved in 34%. Younger children with more serve fibrosis at time of 
biopsy may progress more readily and it is likely that in these selected children, the effects of genetic variants on 
susceptibility may outweigh environmental factors.   
 
Lifestyle change resulting in weight loss is an effective way of reversing or stabilising disease. A small number 
of trials in children have demonstrated results. In an Italian study of 84 children, weight loss average of 4kg over 
a 12 months period resulted in an improvement in ALT and ultrasound features of steatosis (61). There was a drop 
out weight of 30%. Another paediatric study of intensive lifestyle intervention in North America achieved 
improvement in BMI z-score with a decrease of 0.1 U (p<0.05) baseline to one year and decrease in ALT in 69 
% of the follow up cohort. There was a 53% drop out rate however (62). 
 
These results are reflected in the literature regarding adults with NAFLD;  a metanalysis of studies achieving 
weight loss of 5% or more resulted in improvement in steatosis whereas 7% weight loss resulted in improvement 
in steatohepatitis and in those with 10% weight loss, all features of NAFLD were reversed or stabilised (63). In 
a prospective study in adults these outcomes were confirmed (64). There was a high drop-out rate however and 
only 50% successfully achieved 7% weight loss or more.  Of note in 94% of those who achieved 5% weight 
loss, fibrosis stabilised or reversed.  
The success of weight loss alone on the outcome of patients with NAFLD is remarkable, yet the barriers to achieve 
this for all patients have not yet been adequately addressed. It is known that the co-existence of major depressive 
disorder, for example, is a major factor in the failure of lifestyle treatment of NAFLD. Willingness to engage in 
the programme and readiness to change are naturally crucial. The window of opportunity for many may be during 
childhood and early adolescent window as the likelihood of overweight children becoming over weight adults in 
> 80%.  
 
There is a burgeoning industry in developing drugs and compounds to treat NAFLD given the inability of many 
to lose weight. In children neither the TONIC trial (comparing metformin, vitamin E and placebo)(65) and the 
CYnCH trial (comparing cysteamine bitartrate and placebo)(66) reached their primary outcome measure. The use 
of vitamin E in improving some parameters of histology(ballooning) demonstrated statistical significance.  
Newer, more targeted compounds such as FXR agonists, antifibrotic drugs and certain inflammation inhibitors 
show some promise in preclinical and early clinical trial but use in children have not yet been studied.  
 Bariatric surgery has been clearly shown to reverse the disease (6, 67), it is not clear whether this effect is via 
decreased intake / appetite control nor via other disruption of metabolic pathways by banding or by bypassing the 
stomach.  
 
The opportunities to use intensive lifestyle change and maintenance of the lifestyle change through family 
education, counselling and an individualised approach are stark. Undoubtedly deprivation and easy availability of 
ultra-processed in expensive foodstuffs is impossible to tackle at an individual level and we need to exert our 
challenge at a societal level.  
 
Conclusions  
Paediatric NAFLD is a prevalent condition world-wide. Though it shares many features with adult – onset disease, 
paediatric NAFLD has important differences. In particular early life influences and susceptibilities and an 
approach to diagnosis and management need to be considered. There is a real opportunity to reverse the course of 
the disease in childhood and paediatricians should be aware and ready to act.  
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 Table 1: Differential diagnosis of fatty liver in children and young people.  
Differential diagnosis Diagnosis 
Wilson disease Low ceruloplasmin, high urinary or tissue copper, 
mutational analysis 
Alpha 1 antitrypsin deficiency Phenotype ?Genotype 
Drugs – steroids, amiodarone, 
alcohol, methotrexate, MDMA 
(ecstasy), l-asparaginase, vitamin E, 
valproate, tamoxifen,  
antiretrovirals 
History 
Cystic Fibrosis associated liver 
disease 
History / sweat test or mutational analysis  
Malnutrition History  
Coeliac disease Tissue transglutaminase / IgA, HLA typing, jejunal 
biopsy 
Hepatitis C HCV antibody status 
Parenteral Nutrition associated liver 
disease 
History 
Mitochondrial disease / fatty acid 
oxidase deficiency 
Lactate, acylcarnitines, respiratory chain enzymes, 
mutational analysis  
Metabolic disease: Lysosomal acid 
lipase deficiency (Cholesterol Ester 
Storage Disease) 
White cell enzymes, mutational analysis 
Galactosaemia Gal-1-PUT  
Fructosaemia Enzymology 
Glycogen storage disease White cell enzymes, mutational analysis 
Peroxisomal disorders Very long chain fatty acids, mutational analysis 
Mauriac syndrome History of type 1 diabetes 
Hypobetalipoproteinaemia/ 
abetalipoproteinaemia  
Low lipid levels, reduced / absent Apo1B, \ mutational 
analysis  
Lipodystrophies Mutational analysis 
Schwachman syndrome Pancreatic insufficiency / mutational analysis 
 
 
